切换至 "中华医学电子期刊资源库"

中华卫生应急电子杂志 ›› 2023, Vol. 09 ›› Issue (05) : 263 -269. doi: 10.3877/cma.j.issn.2095-9133.2023.05.002

论著

钙卫蛋白对外科术后脓毒症患者的早期诊断价值
高榕悦1, 韩玉珍1, 张晓珂1, 游潘1, 侯舒雅1, 袁懿昕1, 李文雄1, 黄立锋1,()   
  1. 1. 100020 北京,首都医科大学附属北京朝阳医院重症医学科
  • 收稿日期:2023-09-30 出版日期:2023-10-18
  • 通信作者: 黄立锋

Calprotectin as an early diagnostic marker for sepsis in post-operative patients

Rongyue Gao1, Yuzhen Han1, Xiaoke Zhang1, Pan You1, Shuya Hou1, Yixin Yuan1, Wenxiong Li1, Lifeng Huang1,()   

  1. 1. Intensive Care Unit, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100020, China
  • Received:2023-09-30 Published:2023-10-18
  • Corresponding author: Lifeng Huang
引用本文:

高榕悦, 韩玉珍, 张晓珂, 游潘, 侯舒雅, 袁懿昕, 李文雄, 黄立锋. 钙卫蛋白对外科术后脓毒症患者的早期诊断价值[J/OL]. 中华卫生应急电子杂志, 2023, 09(05): 263-269.

Rongyue Gao, Yuzhen Han, Xiaoke Zhang, Pan You, Shuya Hou, Yixin Yuan, Wenxiong Li, Lifeng Huang. Calprotectin as an early diagnostic marker for sepsis in post-operative patients[J/OL]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2023, 09(05): 263-269.

目的

本研究拟检测外科术后脓毒症患者血浆钙卫蛋白含量,阐明钙卫蛋白对脓毒症的早期诊断价值。

方法

前瞻性纳入外科术后转入重症医学科的成人患者205例,其中男性151例,女性54例;年龄24~95岁,平均(64.68±14.46)岁。按照患者在ICU期间是否发生脓毒症,将入组患者分为脓毒症组与非脓毒症组,其中脓毒症组100例,非脓毒症组105例。收集所有患者入ICU 24 h内的静脉血标本,收集脓毒症组患者确诊脓毒症24 h内的静脉血标本,并测定血浆钙卫蛋白及其他感染相关指标水平。通过单因素及多因素Logistic回归分析,确定发生脓毒症的危险因素。在此基础上绘制钙卫蛋白诊断脓毒症的ROC曲线,评价其对脓毒症的诊断价值。

结果

与非脓毒症组相比,脓毒症组患者血钙卫蛋白、降钙素原(PCT)水平明显升高(P<0.01)。多因素Logistic回归分析显示,入组当天最高SOFA评分、急诊手术、糖尿病、血钙卫蛋白、PCT、白细胞计数是术后发生脓毒症的独立危险因素。钙卫蛋白诊断术后发生脓毒症的AUC为0.81(95%CI 0.75,0.86),PCT诊断术后发生脓毒症的AUC为0.78(95%CI 0.71,0.84),钙卫蛋白联合PCT诊断术后发生脓毒症的AUC为0.87(95%CI 0.81,0.92)。

结论

外科术后患者血浆钙卫蛋白水平对脓毒症有诊断价值,且与PCT联合时早期诊断价值更高。

Objective

To investigate the diagnostic value of calprotectin for sepsis.

Methods

We prospectively enrolled adult patients who were transferred to intensive care unit(ICU)after surgery.205 patients after surgery were included in this study. There were 100 patients in the sepsis group and 105 patients in the non-sepsis group. Venous blood samples were collected from all patients within 24 hours after admission to ICU. We also collected venous blood samples from patients in the sepsis group within 24 hours after diagnosis of sepsis. Then calprotectin levels were measured. We compared baseline data and laboratory indexes between the two groups immediately after enrollment. Risk factors of sepsis were evaluated by univariate and multivariate Logistic regression analysis. We drew ROC curve of calprotectin for sepsis diagnosis to evaluate its diagnostic value.

Results

The sepsis group had significantly higher serum levels of calprotectin and PCT than the non-sepsis group(P<0.01). Multivariate logistic regression analysis revealed that SOFA score, emergency surgery, diabetes, serum calprotectin, PCT and white blood cell were independent risk factors for sepsis after major surgery. The AUC of calprotectin for diagnosing sepsis after major surgery was 0.81(95% CI 0.75, 0.86), and that of PCT was 0.78(95% CI 0.71, 0.84). The AUC of calprotectin combined with PCT for diagnosing sepsis after major surgery was 0.87 (95% CI 0.81, 0.92).

Conclusions

Plasma calprotectin is a diagnostic marker for sepsis after surgery, and its early diagnostic value is higher when combined with PCT.

表1 脓毒症组与非脓毒症组患者的基线资料[例(%)]
组别 例数 性别 年龄(岁) BMI(kg/m2) 手术科室
胸外科 普外科 神经外科 泌尿外科 骨科
脓毒症组 100 26(26.0) 74(74.0) 66(56,80) 23.8(20.1,26.0) 2(2.0) 64(64.0) 8(8.0) 16(16.0) 8(8.0)
非脓毒症组 105 28(26.7) 77(73.3) 64(58,69) 22.0(19.8,27.6) 14(13.3) 70(66.7) 7(6.7) 0 28(28.0)
Z2   0.01 0.53 0.71 9.14 0.16 0.13 18.22 12.33
P   >0.05 >0.05 >0.05 <0.05 >0.05 >0.05 <0.05 <0.05
组别 例数 手术类别 基础疾病
其他 急诊手术 高血压 糖尿病 冠心病 慢性阻塞性肺疾病 脑血管病 慢性肾脏病 肿瘤
脓毒症组 100 4(4.0) 58(58.0) 48(48.0) 26(26.0) 28(28.0) 2(2.0) 26(26.0) 8(8.0) 32(32.0)
非脓毒症组 105 0 14(13.3) 42(40.0) 49(46.7) 0 7(6.7) 21(20) 0 56(53.3)
Z2   2.45 44.85 1.33 9.43 34.05 1.66 1.04 6.74 9.51
P   >0.05 <0.05 >0.05 <0.05 <0.05 >0.05 >0.05 <0.05 <0.05
组别 例数 基础疾病 ICU治疗 临床危重评分 实验室检查
其他 使用血管活性药 机械通气 肾脏替代治疗 SOFA评分 APACHEⅡ评分 钙卫蛋白(ng/mL) PCT(ng/mL) 白细胞(×109/L)
脓毒症组 100 22(22.0) 42(42.0) 46(46.0) 16(16.0) 7(5,9) 14(11,19) 1 855.50(1 137.53,2 922.51) 7.34(1.90,68.87) 13.40(8.88,20.54)
非脓毒症组 105 14(13.3) 14(13.3) 21(20.0) 0 4(3,5) 12(9,13) 702.48(561.56,1 318.83) 1.38(0.49,2.15) 9.61(6.48,14.72)
Z2   2.66 21.20 15.74 18.22 47.94 18.36 57.81 14.84 17.14
P   >0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05
组别 例数 实验室检查 临床结局
血小板(×109/L) 乳酸(mmol/L) 肌酐(μmmol/L) 白蛋白(g/L) ICU停留时间(d) 总住院时长(h) 28 d内死亡
脓毒症组 100 137(102,214) 2.50(1.50,5.13) 83.8(66.8,140.6) 29.1(26.5,32.9) 4.5(3.2,10.6) 21.7(12.2,39.2) 14(14)
非脓毒症组 105 104(39,223) 2.00(1.10,4.80) 67.6(47.4,80.9) 33.6(24.3,35.2) 3.2(2.5,4.0) 26.5(16.5,46.3) 0
Z2   10.13 3.03 41.37 16.33 19.68 8.62 15.78
P   <0.05 >0.05 <0.05 <0.05 <0.05 <0.05 <0.05
表2 外科大手术后患脓毒症危险因素的Logistic回归分析
图1 钙卫蛋白与PCT诊断脓毒症的ROC曲线
表3 钙卫蛋白与PCT诊断脓毒症的ROC曲线分析
图2 不同结局脓毒症患者血钙卫蛋白水平
1
Singer MDeutschman CSSeymour CW,et al.The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA2016315(8):801-810.
2
Zampieri FGBagshaw SMSemler MW.Fluid therapy for critically Ill adults with sepsis:a review[J].JAMA2023329(22):1967-1980.
3
Evans LRhodes AAlhazzani W,et al.Surviving sepsis campaign:international guidelines for management of sepsis and septic shock 2021[J].Intensive Care Med202147(11):1181-1247.
4
Parli SETrivedi GWoodworth A,et al.Procalcitonin:usefulness in acute care surgery and trauma[J].Surg Infect(Larchmt)201819(2):131-136.
5
Gopal NChauhan NJain U,et al.Advancement in biomarker based effective diagnosis of neonatal sepsis[J].Artif Cells Nanomed Biotechnol202351(1):476-490.
6
Fleischmann CScherag AAdhikari NK,et al.Assessment of global incidence and mortality of hospital-treated sepsis.current estimates and limitations[J].Am J Respir Crit Care Med2016193(3):259-272.
7
Kingsley MKBhat BVBadhe BA,et al.Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses[J].Sci Rep202010(1):2947.
8
Huang LLi JHan Y,et al.Serum calprotectin expression as a diagnostic marker for sepsis in postoperative intensive care unit patients[J].J Interferon Cytokine Res201636(10):607-616.
9
Wirtz THBuendgens LWeiskirchen R,et al.Association of serum calprotectin concentrations with mortality in critically Ill and septic patients[J].Diagnostics(Basel)202010(11):990.
10
Denstaedt SJSpencer-Segal JLNewstead MW,et al.S100A8/A9 drives neuroinflammatory priming and protects against anxiety-like behavior after sepsis[J].J Immunol2018200(9):3188-3200.
11
Ulas TPirr SFehlhaber B,et al.S100-alarmin-induced innate immune programming protects newborn infants from sepsis[J].Nat Immunol201718(6):622-632.
12
Larsson ATydén JJohansson J,et al.Calprotectin is superior to procalcitonin as a sepsis marker and predictor of 30-day mortality in intensive care patients[J].Scand J Clin Lab Invest202080(2):156-161.
13
Granholm AMøller MHKrag M,et al.Predictive performance of the simplified acute physiology score(SAPS)II and the initial sequential organ failure assessment(SOFA)score in acutely Ill intensive care patients:post-hoc analyses of the SUP-ICU inception cohort study[J].PLoS One201611(12):e0168948.
14
Liu ZMeng ZLi Y,et al.Prognostic accuracy of the serum lactate level,the SOFA score and the qSOFA score for mortality among adults with Sepsis[J].Scand J Trauma Resusc Emerg Med201927(1):51.
15
Peng XChen CChen J,et al.Tree-based,two-stage risk factor analysis for postoperative sepsis based on Sepsis-3 criteria in elderly patients:A retrospective cohort study[J].Front Public Health2022(10):1006955.
16
Balintescu ALind MFranko MA,et al.Glycemic control and risk of sepsis and subsequent mortality in type 2 diabetes[J].Diabetes Care202245(1):127-133.
17
Kotagal MSymons RGHirsch IB,et al.Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes[J].Ann Surg2015261(1):97-103.
18
Dai JKumbhare AYoussef D,et al.Intracellular S100A9 promotes myeloid-derived suppressor cells during late sepsis[J].Front Immunol2017(8):1565.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志(电子版), 2024, 21(11): 1089-1091.
[2] 唐金侨, 叶宇佳, 王港, 赵彬, 马艳宁. 医学影像学检查方法在颞下颌关节紊乱病中临床应用研究进展[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 406-411.
[3] 中国医师协会肝癌专业委员会. 肝细胞癌伴微血管侵犯诊断和治疗中国专家共识(2024版)[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 313-324.
[4] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[5] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[6] 熊鹰, 林敬莱, 白奇, 郭剑明, 王烁. 肾癌自动化病理诊断:AI离临床还有多远?[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 535-540.
[7] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[8] 郑大雯, 王健东. 胆囊癌辅助诊断研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 769-773.
[9] 王秋生. 胆道良性疾病诊疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 779-782.
[10] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[11] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[12] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[13] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[14] 陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
[15] 胡云鹤, 周玉焯, 付瑞瑛, 于凡, 李爱东. CHS-DRG付费制度下GB1分组住院费用影响因素分析与管理策略探讨[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 568-574.
阅读次数
全文


摘要